Roche to invest 190 million Swiss Francs in new production facility in Basel
Basel, 14 October 2013
Roche today announced plans to invest 190 million Swiss francs in the construction of a new production facility in Basel, which will support the manufacturing of antibody-drug conjugate medicines. This development is part of an 800 million Swiss franc investment by Roche to increase production capabilities for its biologic medicines across its global manufacturing network. The investment in Basel is expected to create 50 jobs.
“The investment in the manufacturing of antibody-drug conjugates in Basel not only highlights the faith we have in the role of these treatments in future medical practice, but the commitment we have in the Basel site,” says Matthias M. Baltisberger, Site Head at Roche Basel. “We expect this exciting development to create 50 highly skilled jobs including roles for technicians, scientists, engineers and quality professionals.”
Construction of the new production facility is planned to begin in January 2014 and be ready for use by August 2016, subject to official approval.
About the antibody-drug conjugate production facility (Building 91)
The new production facility for antibody-drug conjugates will be an eight-storey, high-quality facility, which will replace a building on the northern part of the Basel site, pending its planned demolition by end of 2013. It will offer a gross surface area of around 15,000 m2 and house two antibody-drug conjugate production lines.
Architecturally, the new facility will be in the style of existing buildings in Basel. In the course of the planning process, close attention will be paid to safety, health and environmental protection.
Antibody-drug conjugates can attach to certain types of cancer cells and deliver chemotherapy directly to them, offering patients a chance to extend their lives with fewer of the side effects commonly experienced with chemotherapy.
About investments to the global biologic manufacturing network
Roche plans to invest 800 million Swiss francs within its global manufacturing network to increase production capabilities for its biologic medicines over the next five years. The investment will be spread across sites in Penzberg, Germany, Basel, Switzerland, as well as Vacaville and Oceanside in the U.S. Approximately 470 new jobs are expected to be created in conjunction with the facility expansions.
The investment will ensure the future supply of licensed biologic medicines, such as RoACTEMRA (tocilizumab), Kadcyla (trastuzumab emtansine) and Perjeta (pertuzumab), alongside providing a strong foundation for the delivery of 39 investigational biologic medicines in the Roche pipeline.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.